Form 4: Dianthus Therapeutics Director Acquires Stock Options

Director Steven J. Romano acquired stock options for 12,500 shares of Dianthus Therapeutics common stock on May 22, 2025.

Summary

• Steven J. Romano, a director of Dianthus Therapeutics, acquired stock options on May 22, 2025.
• The options are for 12,500 shares of Dianthus Therapeutics common stock.
• The exercise price of the stock options is $18.36.
• The options vest on the earlier of the first anniversary of the grant date or the Issuer's 2026 Annual Meeting of Stockholders, contingent upon continued service.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a routine disclosure of stock option grants to a director.

Future Outlook

The vesting of the stock options is contingent upon the director's continued service to the company.

Industry Context

This is a standard Form 4 filing, indicating a change in beneficial ownership by a company insider. Such filings are common and provide transparency into insider transactions.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder confidence due to the director's increased stake in the company.

Key Dates

Keywords

stock options, director, Dianthus Therapeutics, DNTH, Form 4, Romano, insider trading